Fresh off pos­i­tive Nu­plazid da­ta, Aca­dia adds new clin­i­cal drug from Van­der­bilt in mile­stone-heavy deal

Aca­dia Phar­ma’s pri­ma­ry strat­e­gy over the last few years has been to get its con­tro­ver­sial Parkin­son’s drug ap­proved for oth­er dis­eases, in­clud­ing de­pres­sion and schiz­o­phre­nia. Now, for the first time in 2 years, the com­pa­ny is adding a new chem­i­cal to its pipeline.

Aca­dia has agreed to a mile­stone-heavy deal with Van­der­bilt Uni­ver­si­ty on a pro­gram to al­loster­i­cal­ly tar­get a re­cep­tor called mus­carinic M1, a po­ten­tial path to­ward treat­ing cer­tain cen­tral ner­vous sys­tem dis­or­ders, in­clud­ing Alzheimer’s and schiz­o­phre­nia. The deal will pay Van­der­bilt $10 mil­lion, with $515 mil­lion in po­ten­tial mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.